Tissue plasminogen activator therapy for the eye
Open Access
- 1 November 2005
- journal article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (11) , 1390-1391
- https://doi.org/10.1136/bjo.2005.074401
Abstract
The systemic (intravenous) administration of genetically modified (recombinant) tissue plasminogen activator (tPA) for thrombolysis in coronary arteries was approved by the US Federal Drug Administration in 1988. Since then, use of this approved drug has been extended to many non-approved indications, especially in the eye.1Keywords
This publication has 37 references indexed in Scilit:
- THE EFFECT OF UROKINASE ON CENTRAL CORNEAL THICKNESS AND VITREOUS HAEMORRHAGEActa Ophthalmologica, 2009
- Retinal toxicity of intravitreal tissue plasminogen activator: Case report and literature reviewOphthalmology, 2003
- PEDIATRIC CATARACTSOphthalmology Clinics of North America, 2001
- Recombinant tissue plasminogen activator following paediatric cataract surgeryBritish Journal of Ophthalmology, 2000
- Bandförmige Keratopathie nach Behandlung der postoperativen Fibrinreaktion mit GewebeplasminogenaktivatorKlinische Monatsblätter für Augenheilkunde, 1996
- Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cellsThrombosis Research, 1990
- Filtering Bleb Thrombolysis with Tissue Plasminogen ActivatorAmerican Journal of Ophthalmology, 1988
- Use of Tissue Plasminogen Activator in Experimental HyphemaArchives of Ophthalmology (1950), 1987
- Tissue plasminogen activator in avascular tissues of the eye: a quantitative study of its activity in the cornea, lens, and aqueous and vitreous humors of dog, calf, and monkeyExperimental Eye Research, 1987
- TOXIC OCULAR EFFECTS OF TWO FIBRINOLYTIC DRUGSActa Ophthalmologica, 1983